"Late-Breaking is intended for results from major clinical trials & epidemiological studies and have not been published (or will be published) anywhere else prior to SCM20."

This is the same policy for all late breaking sessions at science conferences. Technically, none of the MACE data for the CKD sub-group was published in a scientific journal or presented at a scientific meeting. However, Resverlogix did present this MACE data for the CKD sub-group in a post-AHA corporate presentation. I am pretty sure that the not published anywhere guidance also applies to corporate presentations. So I do tend to agree with you Growacet, that this NKF late breaker is a set up for significantly new data on the CKD sub-group (beyond just MACE data) not previously revealed.

BDAZ